9 MAKO Surgical Corp. Analyst Ratings, Earnings, Dividends and Insider Trades | $MAKO | NASDAQ:MAKO | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact MAKO Surgical Corp. Company Profile (NASDAQ:MAKO) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for MAKO Surgical Corp. (NASDAQ:MAKO) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 8 Hold Rating(s), 3 Buy Rating(s)Consensus Rating:Hold (Score: 2.27)Consensus Price Target: $18.44 38.50% downside) Analysts' Ratings History for MAKO Surgical Corp. (NASDAQ:MAKO) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare10/10/2013Piper JaffrayDowngradeOverweight -> Neutral$26.00 -> $30.00View 10/1/2013ZacksUpgradeUnderperform -> Neutral$30.20View 9/26/2013Wells Fargo & Co.DowngradeOutperform -> Market Perform$1.40View 9/25/2013William BlairDowngradeOutperform -> Market PerformView 9/25/2013Summer StreetDowngradeBuy -> NeutralView 8/8/2013Needham & CompanyInitiated CoverageHoldView 8/2/2013ZacksDowngradeNeutral -> Underperform$13.70View 8/1/2013OppenheimerBoost Price TargetOverweight$23.00 -> $26.00View 7/31/2013WallachBeth CapitalBoost Price TargetHold$12.00 -> $14.00View 7/31/2013Canaccord GenuityBoost Price TargetHold$12.00 -> $13.50View 6/25/2013First AnalysisInitiated CoverageOverweightView 5/28/2013Wells Fargo & Co.UpgradeMarket Perform -> OutperformView 5/8/2013OppenheimerLower Price TargetMarket Perform$13.00 -> $12.00View 4/22/2013WallachBeth CapitalInitiated CoverageHold$12.00View 4/9/2013MizuhoUpgradeNeutral -> Buy$12.00 -> $14.00View 2/27/2013MizuhoLower Price TargetNeutral$13.00 -> $12.00View 2/27/2013Canaccord GenuityLower Price TargetHold$13.00 -> $12.00View 2/27/2013OppenheimerLower Price TargetMarket Perform$14.00 -> $13.00View 2/27/2013William BlairReiterated RatingOutperformView 2/27/2013Piper JaffrayReiterated RatingOverweight$23.00View 1/28/2013Piper JaffrayLower Price Target$28.00 -> $23.00View 1/22/2013William BlairReiterated RatingOutperformView 1/7/2013Piper JaffrayReiterated RatingOverweightView 12/20/2012Piper JaffrayReiterated RatingOverweight$28.00View 12/3/2012Wells Fargo & Co.Reiterated RatingMarket PerformView 11/20/2012Piper JaffrayReiterated RatingOverweight$28.00View 11/14/2012Goldman SachsReiterated RatingNeutralView 11/14/2012Goldman SachsLower Price Target$16.00View 11/14/2012William BlairReiterated RatingOutperformView 11/8/2012Canaccord GenuityReiterated RatingHoldView 11/5/2012Summer StreetUpgradeNeutral -> Buy$25.00View 9/20/2012JPMorgan Chase & Co.Reiterated RatingNeutral -> NeutralView 9/19/2012Goldman SachsBoost Price TargetNeutral$15.00 -> $17.00View 9/4/2012Wells Fargo & Co.Initiated CoverageMarket PerformView 8/30/2012Goldman SachsReiterated RatingNeutralView 8/30/2012Dougherty & CoDowngradeBuy -> Neutral$18.00View 8/2/2012Canaccord GenuityReiterated RatingHoldView 8/2/2012MizuhoLower Price TargetNeutral$15.00 -> $13.00View 7/10/2012Dougherty & CoReiterated RatingBuyView 7/10/2012Canaccord GenuityReiterated RatingHoldView 7/10/2012Summer StreetDowngradeBuy -> NeutralView 7/10/2012MizuhoLower Price TargetNeutral$30.00 -> $15.00View 7/10/2012Goldman SachsDowngradeBuy -> Neutral$17.00View 6/12/2012Dougherty & CoInitiated CoverageBuyView 6/7/2012William BlairUpgradeMarket Perform -> OutperformView 5/23/2012Goldman SachsReiterated RatingBuyView 5/8/2012Goldman SachsLower Price Target$49.00 -> $42.00View 5/8/2012JPMorgan Chase & Co.Lower Price Target$37.00 -> $33.00View 5/8/2012Piper JaffrayLower Price Target$50.00 -> $49.00View 5/8/2012Canaccord GenuityReiterated RatingHoldView 5/8/2012MizuhoDowngradeBuy -> Neutral$54.00 -> $30.00View 5/8/2012William BlairDowngradeOutperform -> Market PerformView 4/12/2012OppenheimerInitiated CoverageMarket PerformView 4/3/2012MizuhoInitiated CoverageBuy$54.00View (Data available from 3/8/2012 forward) Earnings History for MAKO Surgical Corp. (NASDAQ:MAKO)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare11/5/2013Q313($0.12)($0.45)$33.00 million$22.76 millionViewN/AView 7/30/2013Q2 2013($0.22)($0.42)$28.53 million$28.20 millionViewN/AView 5/7/2013Q1 2013($0.19)($0.21)$24.82 million$24.81 millionViewN/AView 2/26/2013Q4 2012($0.13)($0.13)$30.80 million$30.28 millionViewN/AView 11/7/2012Q312($0.16)($0.15)$27.48 million$29.17 millionViewN/AView 8/1/2012($0.22)($0.20)ViewN/AView 5/7/2012($0.20)($0.28)ViewN/AView 3/6/2012($0.14)($0.14)ViewN/AView 11/9/2011($0.23)($0.24)ViewN/AView 8/8/2011($0.24)($0.24)ViewN/AView 5/3/2011($0.24)($0.27)ViewN/AView (Data available from 1/1/2011 forward) Dividend History for MAKO Surgical Corp. (NASDAQ:MAKO)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for MAKO Surgical Corp. (NASDAQ:MAKO)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare11/15/2012William D PruittDirectorBuy10,000$13.45$134,500.00View 11/14/2012Christopher C DeweyDirectorBuy25,000$13.15$328,750.00View (Data available from 1/1/2013 forward) About MAKO Surgical Corp. MAKO Surgical Corp. (MAKO) is a medical device company, which markets its advanced robotic arm solution, joint specific applications for the knee and hip and orthopedic implants for orthopedic procedures. The Company offers MAKOplasty, a restorative surgical solution that enables orthopedic surgeons to treat patient specific, osteoarthritic disease. MAKOplasty is performed using the Company's RIO Robotic Arm Interactive Orthopedic system (RIO). The RIO is a technology platform that utilizes tactile guided robotic arm technology and patient specific planning and visualization to offer reproducible precision to surgeons. The RIO is used to treat early to mid-stage osteoarthritic knee disease and osteoarthritic hip disease. The Company offers MAKOplasty Partial Knee Arthroplasty, or MAKOplasty PKA, and MAKOplasty Total Hip Arthroplasty, or MAKOplasty THA. Headlines: (2/16) Former Mako guru has a new venture (3/5) Stryker Continues Acquisition Spree but Shares Fall (3/5) Stryker Continues Acquisition Spree but Shares Fall - Analyst Blog (3/6) United States Knee Reconstruction Market Outlook to 2020 (2/18) Stryker Announces Definitive Agreement to Acquire Berchtold Holding, AG (3/7) Stryker Completes Acquisition of Pivot Medical, Inc. (2/25) Stryker to Present at Investor Conference (2/7) Stryker to Present at Investor Conferences Industry, Sector and Symbol: Sector: Healthcare Industry: Health Care Equipment & Supplies Sub-Industry: Health Care Equipment Exchange: NASDAQ Symbol: MAKO CUSIP: 56087910 Key Metrics: Previous Close: $29.9950 Day Moving Average: $29.9103200 Day Moving Average: $20.5594 P/E Ratio: N/AP/E Growth: N/AMarket Cap: $N/ACurrent Quarter EPS Consensus Estimate: $0.00 EPS Additional Links: View MAKO on Google FinanceView MAKO on Yahoo FinanceView MAKO's Company Profile on ReutersSearch for MAKO Surgical Corp. on Google MAKO Surgical Corp. (NASDAQ:MAKO) Chart for Saturday, March, 8, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.